• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在难治性精神分裂症中,阳性症状与临床医生的整体印象相关。

Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia.

作者信息

Lee Jimmy, Fervaha Gagan, Takeuchi Hiroyoshi, Powell Valerie, Remington Gary

机构信息

From the *Department of General Psychiatry 1, Institute of Mental Health; †Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore; ‡Schizophrenia Division, Centre for Addiction and Mental Health; §Institute of Medical Science, University of Toronto, Toronto, Canada; ∥Department of Neuropsychiatry, School of Medicine, Keio University Tokyo, Japan; and ¶Department of Psychiatry, University of Toronto, Toronto, Canada.

出版信息

J Clin Psychopharmacol. 2015 Jun;35(3):237-41. doi: 10.1097/JCP.0000000000000310.

DOI:10.1097/JCP.0000000000000310
PMID:25839337
Abstract

Previous investigations on the relationship between global rating measures and symptoms have not considered the additional role of functioning. In this naturalistic study, we examined the relationship between symptom domains and functioning on Clinical Global Impression scales for severity (CGI-S) and improvement (CGI-I) in a sample of patients with schizophrenia assessed to be treatment resistant. Participants were patients with a diagnosis of schizophrenia or schizoaffective disorder who failed 2 prior antipsychotic trials and were considered candidates for clozapine. They were assessed on the 18-item Brief Psychiatric rating Scale (BPRS), Social Occupational Functioning Assessment Scale (SOFAS), and CGI-S at baseline. A subset of patients was followed up at 6 weeks after initiation of clozapine and assessed on the CGI-I. The independent effects of symptom domains and functioning on the CGI scales were examined via multivariate regression models. Brief Psychiatric rating Scale positive factor (P < 0.001) and SOFAS (P < 0.001) scores were significant determinants of CGI-S at baseline. Multivariate models suggested that relative change measures had a better fit for the CGI-I compared to absolute change measures (R = 0.72 vs R = 0.61, respectively). Improvements in BPRS positive (P < 0.001) and affect (P = 0.002) factors and SOFAS (P = 0.030) scores were significant determinants of CGI-I. Ratings of 1 and 2 on the CGI-I corresponded to a mean relative change in the BPRS total of 65% and 41%, respectively. Positive symptoms were a key determinant of clinicians' impression of severity and improvement in this study. Although psychosocial functioning played a large part in determining severity, it was not as significant in the assessment of improvement.

摘要

先前关于整体评定指标与症状之间关系的研究并未考虑功能的额外作用。在这项自然主义研究中,我们在一组被评估为治疗抵抗的精神分裂症患者样本中,考察了症状领域与临床总体印象量表中严重程度(CGI-S)及改善程度(CGI-I)方面功能之间的关系。参与者为诊断为精神分裂症或分裂情感性障碍的患者,他们之前两次抗精神病药物试验均失败,被认为是氯氮平治疗的候选者。在基线时,他们接受了18项简明精神病评定量表(BPRS)、社会职业功能评估量表(SOFAS)和CGI-S评估。一部分患者在氯氮平治疗开始6周后进行随访,并接受CGI-I评估。通过多元回归模型检验症状领域和功能对CGI量表的独立影响。基线时,简明精神病评定量表阳性因子(P < 0.001)和SOFAS评分(P < 0.001)是CGI-S的显著决定因素。多元模型表明,与绝对变化量度相比,相对变化量度对CGI-I的拟合度更好(R分别为0.72和0.61)。BPRS阳性(P < 0.001)和情感(P = 0.002)因子以及SOFAS评分(P = 0.030)的改善是CGI-I的显著决定因素。CGI-I评分为1和2分别对应BPRS总分平均相对变化65%和41%。在本研究中,阳性症状是临床医生对严重程度和改善情况印象的关键决定因素。虽然心理社会功能在确定严重程度方面起很大作用,但在改善评估中其重要性不那么显著。

相似文献

1
Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia.在难治性精神分裂症中,阳性症状与临床医生的整体印象相关。
J Clin Psychopharmacol. 2015 Jun;35(3):237-41. doi: 10.1097/JCP.0000000000000310.
2
Relationship between clinical improvement and functional gains with clozapine in schizophrenia.精神分裂症中氯氮平的临床改善与功能增益之间的关系。
Eur Neuropsychopharmacol. 2014 Oct;24(10):1622-9. doi: 10.1016/j.euroneuro.2014.08.003. Epub 2014 Aug 12.
3
Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.氯氮平治疗难治性精神分裂症、分裂情感性障碍或精神病性双相障碍患者:一项48个月的自然随访研究。
J Clin Psychiatry. 2003 Apr;64(4):451-8. doi: 10.4088/jcp.v64n0416.
4
Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.口服齐拉西酮治疗精神分裂症或分裂情感性障碍急性加重期住院精神病患者的有效性和耐受性:一项多中心、前瞻性、自然主义研究。
J Clin Psychiatry. 2009 Apr;70(4):509-17. doi: 10.4088/jcp.08m04410. Epub 2009 Apr 7.
5
Linking the PANSS, BPRS, and CGI: clinical implications.将阳性和阴性症状量表(PANSS)、简明精神病评定量表(BPRS)与临床总体印象量表(CGI)相联系:临床意义。
Neuropsychopharmacology. 2006 Oct;31(10):2318-25. doi: 10.1038/sj.npp.1301147. Epub 2006 Jul 5.
6
Is there a linear relationship between the Brief Psychiatric Rating Scale and the Clinical Global Impression-Schizophrenia scale? A retrospective analysis.简明精神病评定量表与临床总体印象-精神分裂症量表之间是否存在线性关系?一项回顾性分析。
BMC Psychiatry. 2010 Dec 7;10:105. doi: 10.1186/1471-244X-10-105.
7
Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.氯氮平治疗难治性精神分裂症中对氯氮平的无应答和病前功能。
Compr Psychiatry. 2010 May-Jun;51(3):298-302. doi: 10.1016/j.comppsych.2009.07.003. Epub 2009 Aug 27.
8
Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.电休克治疗难治性精神分裂症的疗效:一项前瞻性开放试验。
Prog Neuropsychopharmacol Biol Psychiatry. 2003 May;27(3):373-9. doi: 10.1016/S0278-5846(02)00354-8.
9
Switching to ziprasidone in the clinical practice setting: an open-label study.切换到齐拉西酮的临床实践设置:一项开放标签研究。
Int J Psychiatry Med. 2013;45(2):125-42. doi: 10.2190/PM.45.2.c.
10
Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia.精神分裂症患者症状改善与整体疾病严重程度之间的关系。
J Clin Psychopharmacol. 2015 Apr;35(2):128-33. doi: 10.1097/JCP.0000000000000286.

引用本文的文献

1
Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients.难治性近期起病精神病患者的血浆多巴脱羧酶活性
Ther Adv Psychopharmacol. 2019 Sep 6;9:2045125319872341. doi: 10.1177/2045125319872341. eCollection 2019.
2
Basal Exposure Therapy: A New Approach for Treatment-Resistant Patients with Severe and Composite Mental Disorders.基础暴露疗法:治疗难治性重度复合型精神障碍患者的新方法。
Front Psychiatry. 2016 Dec 19;7:198. doi: 10.3389/fpsyt.2016.00198. eCollection 2016.